H.C. Wainwright analyst Oren Livnat assumed coverage of Tarsus Pharmaceuticals (TARS) with a Buy rating and $72 price target The firm likes the company’s Xdemvy impetus in Demodex blepharitis. Xdemvy represents the first and only FDA approved therapy to treat Demodex blepharitis, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Elanco sells royalty, milestone rights for Xdemvy to Blackstone for $295M
- Tarsus Pharmaceuticals’ Earnings Call Highlights Robust Growth
- Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- Tarsus Pharmaceuticals price target raised to $84 from $78 at Guggenheim
- Tarsus Pharmaceuticals Reports Strong Q1 2025 Growth